- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Squamous Non-Small Cell Lung Cancer Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Squamous Non-Small Cell Lung Cancer Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Research Center accounting for % of the Squamous Non-Small Cell Lung Cancer Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While BMS-906024 segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Squamous Non-Small Cell Lung Cancer Therapeutics include Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, and BIND Therapeutics, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Squamous Non-Small Cell Lung Cancer Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Market segment by Application, can be divided into
Research Center
Hospital
Clinic
Market segment by players, this report covers
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Squamous Non-Small Cell Lung Cancer Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Squamous Non-Small Cell Lung Cancer Therapeutics, with revenue, gross margin and global market share of Squamous Non-Small Cell Lung Cancer Therapeutics from 2019 to 2022.
Chapter 3, the Squamous Non-Small Cell Lung Cancer Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Squamous Non-Small Cell Lung Cancer Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Squamous Non-Small Cell Lung Cancer Therapeutics research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Squamous Non-Small Cell Lung Cancer Therapeutics
1.2 Classification of Squamous Non-Small Cell Lung Cancer Therapeutics by Type
1.2.1 Overview: Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type in 2021
1.2.3 BMS-906024
1.2.4 Buparlisib Hydrochloride
1.2.5 FP-1039
1.2.6 Ipilimumab
1.2.7 JNJ-42756493
1.2.8 Lenvatinib
1.2.9 Others
1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market by Application
1.3.1 Overview: Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Research Center
1.3.3 Hospital
1.3.4 Clinic
1.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size & Forecast
1.5 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast by Region
1.5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
1.6.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
1.6.3 Squamous Non-Small Cell Lung Cancer Therapeutics Trends Analysis
2 Company Profiles
2.1 Ascenta Therapeutics, Inc.
2.1.1 Ascenta Therapeutics, Inc. Details
2.1.2 Ascenta Therapeutics, Inc. Major Business
2.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Ascenta Therapeutics, Inc. Recent Developments and Future Plans
2.2 AstraZeneca Plc
2.2.1 AstraZeneca Plc Details
2.2.2 AstraZeneca Plc Major Business
2.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 AstraZeneca Plc Recent Developments and Future Plans
2.3 AVEO Pharmaceuticals, Inc.
2.3.1 AVEO Pharmaceuticals, Inc. Details
2.3.2 AVEO Pharmaceuticals, Inc. Major Business
2.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 AVEO Pharmaceuticals, Inc. Recent Developments and Future Plans
2.4 Bayer AG
2.4.1 Bayer AG Details
2.4.2 Bayer AG Major Business
2.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bayer AG Recent Developments and Future Plans
2.5 BIND Therapeutics, Inc.
2.5.1 BIND Therapeutics, Inc. Details
2.5.2 BIND Therapeutics, Inc. Major Business
2.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 BIND Therapeutics, Inc. Recent Developments and Future Plans
2.6 Boehringer Ingelheim GmbH
2.6.1 Boehringer Ingelheim GmbH Details
2.6.2 Boehringer Ingelheim GmbH Major Business
2.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.7 Bristol-Myers Squibb Company
2.7.1 Bristol-Myers Squibb Company Details
2.7.2 Bristol-Myers Squibb Company Major Business
2.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.8 Eli Lilly and Company
2.8.1 Eli Lilly and Company Details
2.8.2 Eli Lilly and Company Major Business
2.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Eli Lilly and Company Recent Developments and Future Plans
2.9 F. Hoffmann-La Roche Ltd.
2.9.1 F. Hoffmann-La Roche Ltd. Details
2.9.2 F. Hoffmann-La Roche Ltd. Major Business
2.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.10 Five Prime Therapeutics, Inc.
2.10.1 Five Prime Therapeutics, Inc. Details
2.10.2 Five Prime Therapeutics, Inc. Major Business
2.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Five Prime Therapeutics, Inc. Recent Developments and Future Plans
2.11 Genentech, Inc.
2.11.1 Genentech, Inc. Details
2.11.2 Genentech, Inc. Major Business
2.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.11.4 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Genentech, Inc. Recent Developments and Future Plans
2.12 Incyte Corporation
2.12.1 Incyte Corporation Details
2.12.2 Incyte Corporation Major Business
2.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.12.4 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Incyte Corporation Recent Developments and Future Plans
2.13 Johnson & Johnson
2.13.1 Johnson & Johnson Details
2.13.2 Johnson & Johnson Major Business
2.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.13.4 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Johnson & Johnson Recent Developments and Future Plans
2.14 MacroGenics, Inc.
2.14.1 MacroGenics, Inc. Details
2.14.2 MacroGenics, Inc. Major Business
2.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.14.4 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 MacroGenics, Inc. Recent Developments and Future Plans
2.15 Novartis AG
2.15.1 Novartis AG Details
2.15.2 Novartis AG Major Business
2.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.15.4 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Novartis AG Recent Developments and Future Plans
2.16 Oncogenex Pharmaceuticals, Inc.
2.16.1 Oncogenex Pharmaceuticals, Inc. Details
2.16.2 Oncogenex Pharmaceuticals, Inc. Major Business
2.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.16.4 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Oncogenex Pharmaceuticals, Inc. Recent Developments and Future Plans
2.17 PsiOxus Therapeutics Limited
2.17.1 PsiOxus Therapeutics Limited Details
2.17.2 PsiOxus Therapeutics Limited Major Business
2.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
2.17.4 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 PsiOxus Therapeutics Limited Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Squamous Non-Small Cell Lung Cancer Therapeutics Players Market Share in 2021
3.2.2 Top 10 Squamous Non-Small Cell Lung Cancer Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Players Head Office, Products and Services Provided
3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Mergers & Acquisitions
3.5 Squamous Non-Small Cell Lung Cancer Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
6.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country
6.3.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
7.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country
7.3.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region
8.3.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Region (2017-2028)
8.3.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
9.2 South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
9.3 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country
9.3.1 South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country
10.3.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Squamous Non-Small Cell Lung Cancer Therapeutics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. Ascenta Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Ascenta Therapeutics, Inc. Major Business
Table 8. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 9. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. AstraZeneca Plc Corporate Information, Head Office, and Major Competitors
Table 11. AstraZeneca Plc Major Business
Table 12. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 13. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. AVEO Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 15. AVEO Pharmaceuticals, Inc. Major Business
Table 16. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 17. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bayer AG Corporate Information, Head Office, and Major Competitors
Table 19. Bayer AG Major Business
Table 20. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 21. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. BIND Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 23. BIND Therapeutics, Inc. Major Business
Table 24. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 25. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
Table 27. Boehringer Ingelheim GmbH Major Business
Table 28. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 29. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 31. Bristol-Myers Squibb Company Major Business
Table 32. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 33. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 35. Eli Lilly and Company Major Business
Table 36. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 37. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 39. F. Hoffmann-La Roche Ltd. Major Business
Table 40. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 41. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Five Prime Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 43. Five Prime Therapeutics, Inc. Major Business
Table 44. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 45. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Genentech, Inc. Corporate Information, Head Office, and Major Competitors
Table 47. Genentech, Inc. Major Business
Table 48. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 49. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Incyte Corporation Corporate Information, Head Office, and Major Competitors
Table 51. Incyte Corporation Major Business
Table 52. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 53. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 55. Johnson & Johnson Major Business
Table 56. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 57. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. MacroGenics, Inc. Corporate Information, Head Office, and Major Competitors
Table 59. MacroGenics, Inc. Major Business
Table 60. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 61. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 63. Novartis AG Major Business
Table 64. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 65. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Oncogenex Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 67. Oncogenex Pharmaceuticals, Inc. Major Business
Table 68. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 69. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. PsiOxus Therapeutics Limited Corporate Information, Head Office, and Major Competitors
Table 71. PsiOxus Therapeutics Limited Major Business
Table 72. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product and Solutions
Table 73. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 75. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 76. Breakdown of Squamous Non-Small Cell Lung Cancer Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 77. Squamous Non-Small Cell Lung Cancer Therapeutics Players Head Office, Products and Services Provided
Table 78. Squamous Non-Small Cell Lung Cancer Therapeutics Mergers & Acquisitions in the Past Five Years
Table 79. Squamous Non-Small Cell Lung Cancer Therapeutics New Entrants and Expansion Plans
Table 80. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 81. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Type (2017-2022)
Table 82. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Forecast by Type (2023-2028)
Table 83. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022)
Table 84. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Forecast by Application (2023-2028)
Table 85. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 86. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 87. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 88. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 89. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 90. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 91. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 92. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 93. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 94. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 95. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 96. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 97. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 98. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 99. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 100. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 101. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 102. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 103. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 104. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 105. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 106. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 107. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 108. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 109. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 110. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 111. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 112. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 113. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 114. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Picture
Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type in 2021
Figure 3. BMS-906024
Figure 4. Buparlisib Hydrochloride
Figure 5. FP-1039
Figure 6. Ipilimumab
Figure 7. JNJ-42756493
Figure 8. Lenvatinib
Figure 9. Others
Figure 10. Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application in 2021
Figure 11. Research Center Picture
Figure 12. Hospital Picture
Figure 13. Clinic Picture
Figure 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 15. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 16. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Region (2017-2028)
Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Region in 2021
Figure 18. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers
Figure 24. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints
Figure 25. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends
Figure 26. Ascenta Therapeutics, Inc. Recent Developments and Future Plans
Figure 27. AstraZeneca Plc Recent Developments and Future Plans
Figure 28. AVEO Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 29. Bayer AG Recent Developments and Future Plans
Figure 30. BIND Therapeutics, Inc. Recent Developments and Future Plans
Figure 31. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Figure 32. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 33. Eli Lilly and Company Recent Developments and Future Plans
Figure 34. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 35. Five Prime Therapeutics, Inc. Recent Developments and Future Plans
Figure 36. Genentech, Inc. Recent Developments and Future Plans
Figure 37. Incyte Corporation Recent Developments and Future Plans
Figure 38. Johnson & Johnson Recent Developments and Future Plans
Figure 39. MacroGenics, Inc. Recent Developments and Future Plans
Figure 40. Novartis AG Recent Developments and Future Plans
Figure 41. Oncogenex Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 42. PsiOxus Therapeutics Limited Recent Developments and Future Plans
Figure 43. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Players in 2021
Figure 44. Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 45. Global Top 3 Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share in 2021
Figure 46. Global Top 10 Players Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share in 2021
Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 48. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Type in 2021
Figure 49. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share Forecast by Type (2023-2028)
Figure 50. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Application in 2021
Figure 51. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share Forecast by Application (2023-2028)
Figure 52. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 53. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 54. North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 55. United States Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 59. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 60. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 61. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. France Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. United Kingdom Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 67. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 68. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Region (2017-2028)
Figure 69. China Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. India Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Australia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 76. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 77. South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 78. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 83. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. UAE Squamous Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. Methodology
Figure 87. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
